Previous Article | Next Article 
Infect Immun, June 1998, p. 2434-2440, Vol. 66, No. 6
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Structure-Function Relationship of Antibacterial Synthetic
Peptides Homologous to a Helical Surface Region on Human Lactoferrin
against Escherichia coli Serotype O111
Daniel S.
Chapple,1,2,3
David J.
Mason,3
Christopher L.
Joannou,1
Edward W.
Odell,2
Vanya
Gant,3 and
Robert W.
Evans1,*
Metalloprotein Research Group, Division of
Biochemistry and Molecular Biology,1 and
Department of Oral Medicine and
Pathology,2 UMDS, Guy's Hospital, London SE1
9RT, and
Infection and Immunity Laboratory, Division of
Infection, UMDS, St. Thomas's Hospital, London SE1
7EH,3 United Kingdom
Received 18 July 1997/Returned for modification 17 September
1997/Accepted 3 March 1998
 |
ABSTRACT |
Lactoferricin includes an 11-amino-acid amphipathic alpha-helical
region which is exhibited on the outer surface of the amino-terminal lobe of lactoferrin. Synthetic peptides homologous to this region exhibited potent antibacterial activity against a selected range of
both gram-negative and gram-positive bacteria. An analog synthesized with methionine substituted for proline at position 26, which is
predicted to disrupt the helical region, abolished antibacterial activity against Escherichia coli and considerably reduced
antibacterial activity against Staphylococcus aureus and an
Acinetobacter strain. The mode of action of human
lactoferrin peptide (HLP) 2 against E. coli serotype
O111 (NCTC 8007) was established by using flow cytometry, surface
plasmon resonance, and transmission electron microscopy. Flow cytometry
was used to monitor membrane potential, membrane integrity, and
metabolic processes by using the fluorescent probes
bis-1,3-(dibutylbarbituric acid)-trimethine oxonol, propidium iodide, and carbonyl cyanide m-chlorophenylhydrazone,
respectively. HLP 2 was found to act at the cell membrane, causing
complete loss of membrane potential after 10 min and of membrane
integrity within 30 min, with irreversible damage to the cell as shown
by rapid loss of viability. The number of particles, measured by light
scatter on the flow cytometer, dropped significantly, showing that
bacterial lysis resulted. The peptide was shown to bind to E. coli O111 lipopolysaccharide by using surface
plasmon resonance. Transmission electron microscopy revealed bacterial
distortion, with the outer membrane becoming detached from the inner
cytoplasmic membrane. We conclude that HLP 2 causes membrane disruption
of the outer membrane, resulting in lysis, and that structural
considerations are important for antibacterial activity.
 |
INTRODUCTION |
Lactoferrin is an avidly
iron-binding glycoprotein of the transferrin family. It is found at
mucosal surfaces, within the specific granules of neutrophils
(32), and in biological fluids (31), such as milk
(6, 7, 22), from which it was first isolated. Lactoferrin
has been shown to have antimicrobial activity against a broad range of
gram-positive bacteria, gram-negative bacteria, and fungi (3, 5,
24). This activity was attributed to its ability to sequester two
atoms of iron (35), an essential bacterial nutrient, and is
restricted to the apoprotein, with the diferric form being inactive
(3). Lactoferrin has also been shown to act synergistically
with other proteins, such as lysozyme (13) and
immunoglobulin A (1), suggesting that it may damage the cell
wall or outer membrane. Furthermore, lactoferrin binds to lipid A
(2) and porins (15) and induces
lipopolysaccharide (LPS) release from the bacterial wall
(14).
Proteolytic digestion of human lactoferrin in vitro yields a peptide
fragment called lactoferricin H, which has enhanced antimicrobial activity (4). The peptide corresponds partially to a surface helix on lactoferrin distinct from the area of iron binding
(34) and in the region of LPS binding (12). We
have shown that a synthetic 11-amino-acid peptide (previously
designated HLT 2 [34] and now renamed human
lactoferrin peptide [HLP] 2), which includes this LPS binding site,
has potent antibacterial activity against Escherichia coli
(34). The RKVR region found within HLP 2 forms the
glycosaminoglycan binding site of human lactoferrin (28).
A number of other naturally occurring peptides have been shown to have
antibacterial activity. These include magainins (39) from
frogs, cecropins (21) from insects, and mellitin
(19) from bee venom. Although these peptides have little
sequence homology, they have two distinguishing features: a high
content of basic amino acids, such as arginine and lysine, and the
ability to adopt secondary conformations (namely,
-helices and
-sheet structures) in which there is a hydrophilic face of polar and
positively charged residues on an axial plane (20). However,
the three-dimensional structures of these peptides are not always
apparent, as is the case with melittin, which takes up a different
structure in aqueous solution when self-association reactions take
place (monomer to tetramer) (37), or with magainin when
bound to the phosphatidylserine vesicles (33). Cationic
peptides have been shown to form pores in artificial membranes (9,
11, 23), and they can also have specific binding sites on the
outer membranes of bacteria (10). Their antimicrobial
activity is likely to be determined by the mode of interaction with the
bacterial cell membrane (20).
A structural feature of the human lactoferricin loop is the
11-amino-acid
-helical region with an asymmetric cluster of basic amino acids (34). In this study the structure-function
relationships of the lactoferricin-related peptides are considered.
Synthetic peptides homologous to this region and analogs were
synthesized, and their antimicrobial activities against a selected
range of gram-negative and gram-positive microorganisms were assessed. By using E. coli, flow cytometry was used to monitor
changes in bacterial cell wall potential (29, 30) and cell
membrane integrity (17), with specific fluorescent dyes,
transmission electron microscopy (TEM) to detect morphological changes
of bacterial cells, and surface plasmon resonance to detect specific
peptide binding sites. The implications of these findings with respect to the antimicrobial activity of full-length lactoferrin in vivo are
discussed.
 |
MATERIALS AND METHODS |
Peptide synthesis.
Peptides HLP 1, 6, and 7 were synthesized
by using 9-fluorenylmethoxycarbonyl chemistry at Kings College Pharmacy
Department, London, United Kingdom. Peptides were assessed to be >95%
pure by reverse-phase high-pressure liquid chromatography and mass spectrometry. Peptide HLP 2 was synthesized by Neosystem Laboratoire, Strasbourg, France. Peptide HLP 1 corresponded to the loop region of
human lactoferricin (residues 20 to 35;
NH2-FQWQRNMRKVRGPPVS-COOH), HLP 2 corresponded to the
alpha-helical region of the loop in its native conformation (residues
20 to 30; NH2-FQWQRNMRKVR-COOH), HLP 6 had a proline
substituted for methionine in HLP 2 (NH2-FQWQRNPRKVR-COOH), and HLP 7 was the D form of HLP 2.
Bacterial strains.
Staphylococcus aureus NCTC 10571 and E. coli NCTC 8007 and NCTC 10418 were obtained from
the National Collection of Type Cultures, Colindale, United Kingdom.
Clinical isolates of an Acinetobacter sp.,
Enterobacter aerogenes, a Klebsiella sp.,
Providencia stuartii, and Proteus mirabilis were
provided by the Department of Microbiology, St. Thomas's Hospital,
London, United Kingdom. Bacterial cultures were stored at
70°C and
grown on Columbia blood agar at 37°C.
MIC determination.
MICs of each peptide were determined in
96-well plates. Peptides were dissolved in 1% proteose peptone and
serially diluted in microtiter wells to give concentrations of between
1.3 mM and 10 µM in a final volume of 95 µl. Bacteria were
incubated at 37°C overnight in 1% proteose peptone to give
approximately 108 bacteria/ml, and 5 µl was added to each
well. The plates were incubated at 37°C overnight, and growth was
determined by absorbance at 620 nm. Antimicrobial activity was
expressed as the concentration of the peptide required to give no
increase in absorbance at 620 nm following incubation (MIC). The MIC
determination for each peptide was repeated in separate plates at least
four times.
Effects of HLP 2 on membrane integrity and potential.
The
membrane potential and integrity of E. coli NCTC 8007 in the presence of HLP 2 was monitored by using flow cytometry and selected dyes by the method of Mason et al. (30).
E. coli incubated overnight in 1% proteose peptone was
diluted 1:100 with fresh medium and incubated at 37°C to log-phase
growth. Bacteria were washed in fresh medium, and cells were harvested
to give a density of 108 cells/ml. Bacteria were incubated
in different concentrations of HLP 2 in proteose peptone, and aliquots
were withdrawn after 2 h of incubation at 37°C to give a
dose-response assay. Time-response assays were performed at the MIC,
with aliquots taken for analysis immediately (time zero) and at 15, 30, 60, 90, and 120 min. Bacteria were centrifuged at 13,400 × g for 30 s and resuspended in fresh medium before flow
cytometry. Bacterial membrane potential was determined by using the
lipophilic anionic membrane potential-sensitive dye
bis-1,3-(dibutylbarbituric acid)trimethine oxonol
[DiBAC4(3)] (Molecular Probes, Inc.)
(30) at a final concentration of 10 µg/ml. Membrane
integrity was assessed with the cationic nucleic acid binding
fluorescent dye propidium iodide (PI) (Sigma, Poole, United Kingdom)
(17) at a final concentration of 10 µg/ml. Fluorescence was measured with an HS Bryte flow cytometer (Bio-Rad, Hemel Hempstead, United Kingdom) and compared to that of control bacteria. Results are
the means from four separate experiments.
Metabolic activity.
To investigate the effects of low
temperature, cultures of E. coli NCTC 8007 were grown
to log phase in 1% proteose peptone at 37°C, the temperature was
reduced and equilibrated to 4°C, and the cultures were treated with
HLP 2 at the MIC for 2 h. Samples were spun at 13,000 rpm for
30 s at 4°C, and the resulting pellet was resuspended in fresh
cold medium. Parallel samples with E. coli NCTC 8007 incubated at 37°C in the presence of HLP 2 and control samples at 4 and 37°C without HLP 2 were also prepared. Aliquots of each sample
were taken and subjected to flow cytometry in the presence of either
DiBAC4(3) or PI. To determine the effect of the
respiratory poison carbonyl cyanide m-chlorophenylhydrazone (CCCP) (Sigma) (26) on the action of HLP 2, bacterial
samples were treated with 50 µM CCCP with or without the peptide for
10 min at 37°C, and the cells were washed by centrifugation at 13,400 × g for 30 s and resuspended in fresh medium. Aliquots
of each sample were taken, and either DiBAC4(3)
or PI was added for flow cytometric analysis.
Effect of HLP 2 on bacterial lysis and cell morphology.
Bacterial lysis was assessed by reduction in particle number. Cell
morphology was assessed by comparing forward and side light scattering
of bacteria incubated with peptide at the MIC for 2 h with that of
control cultures. TEM was employed to confirm morphological changes of
the bacterial cells. Log-phase E. coli (approximately 108 bacteria/ml) incubated for various times in 1%
proteose peptone with HLP 2 and control cultures were centrifuged at
4,000 × g for 5 min, prefixed in 2.5% glutaraldehyde in
0.2 M phosphate buffer (pH 7.3), postfixed in 0.5% osmium tetroxide in
Millonigs constant-osmolarity phosphate buffer (pH 7.4), and dehydrated in graded ethanol solutions. Pellets were embedded in medium Taab Resin
and polymerized for 24 h at 60°C. Sections (50 nm) were stained
with aqueous uranyl acetate and lead citrate and examined with a
Hitatchi H700 transmission electron microscope.
HLP 2 binding to LPS.
The specificity with which peptide HLP
2 bound to LPS was measured by using surface plasmon resonance on a
Biacore X (Pharmacia Biosensor AB). This measures the change in
refractive index, shown as resonance units, of receptor binding to
ligands on a chip surface (27). E. coli
serotype O111 LPS (Sigma) was dissolved in phosphate-buffered saline
(PBS) (pH 7.4) and equilibrated to saturation over the surface of a
hydrophobic HPA sensor chip (Pharmacia Biosensor AB), to which it binds
by hydrophobic interactions. Following saturation, peptide at various
concentrations was suspended in PBS (pH 7.4) and passed over the coated
chip, and peptide binding was measured as a change in resonance units
by using BIA software. This was subtracted from binding of the peptide
on a blank hydrophobic surface to give the number of resonance units
after nonspecific binding had been taken into account. Experiments were
carried out three times.
 |
RESULTS |
Antibacterial activities of HLPs.
HLP 1, the loop region, was
active against E. coli NCTC 8007 and S. aureus NCTC 10571 with the same potency and had greater activity
against an Acinetobacter strain but had no activity against P. mirabilis (Table 1). HLP 2, the alpha-helical region, had greater activity than HLP 1 against
E. coli NCTC 8007, S. aureus, and the
Acinetobacter strain and showed activity against
E. aerogenes and a Klebsiella strain but had
no activity against P. mirabilis and P. stuartii.
HLP 6, in which methionine 26 was replaced by proline, showed no
activity, up to 1 mM, against either E. coli NCTC 8007 or P. mirabilis and reduced activity (compared with HLP 2)
against S. aureus and the Acinetobacter strain.
The D form of HLP 2 (HLP 7) showed increased activity
against E. coli NCTC 8007 and the
Acinetobacter strain and the same potency against S. aureus as HLP 2 but had no activity against P. mirabilis.
Effects of HLP 2 on the membrane potential and integrity.
The
number of cells in the bacterial population which showed dye-associated
fluorescence in the presence of DiBAC4(3) or PI
was expressed as a percentage. The dose-response assay (Fig. 1a) demonstrated that the addition of HLP
2 to E. coli NCTC 8007 results in 50% fluorescence at
approximately 100 µM (0.15 mg/ml), and in the presence of PI at
approximately 140 µM (0.2 mg/ml), showing that the collapse of
membrane potential and integrity occurred at approximately the same
concentrations. Time-response assays (Fig. 1b) showed that 50%
fluorescence is seen after approximately 8 min in the presence of
DiBAC4(3) and after approximately 35 min in the presence of
PI. Collapse of membrane potential therefore occurred before collapse
of membrane integrity.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 1.
Dose-response (a) and time-response (b) assays, by flow
cytometry, of a starting inoculum of 108 E. coli O111 (NCTC 8007) cells per ml versus HLP 2. The percentages
of fluorescent bacterial cells in the presence of PI ( ) or
DiBAC4(3) ( ) are shown. Results are
means ± standard errors from at least three experiments.
|
|
Metabolic activity.
Inhibition of the metabolic pathways by
addition of the respiratory poison CCCP or of enzymatic pathways by
reduction of the assay temperature to 4°C had no effect on the
activity of HLP 2 (Table 2).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
E. coli fluorescence in the presence of
HLP 2 and CCCP or in the presence of HLP 2 at 4°C determined
by using DiBAC4(3) and PI
|
|
Rate of cell lysis.
The results were plotted as a percentage
of particles compared to that for a control culture which contained no
peptide. The dose-response assay (Fig.
2a) showed that 50% of the particles remained at approximately 140 µM (0.2 mg/ml), and the time-response assay (Fig. 2b) showed that 50% of particles remained after 50 min. A comparison of the time-response assays and
dose-response assays for particle number with the corresponding
DiBAC4(3) and PI assays indicated an
inversely proportional relationship between PI fluorescence (indicative
of membrane integrity) and particle number.

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 2.
(a) Percentages of particles present after incubation
for 2 h of E. coli O111 (NCTC 8007) with various
concentrations of HLP 2 compared to that for the control (containing no
HLP 2), measured by using flow cytometry. (b) Percentages of particles
after incubation of E. coli NCTC 8007 with HLP 2 at the
MIC for various time intervals compared to that for control samples
containing no HLP 2. Experiments were repeated at least three times,
with a starting inoculum of 108 bacteria/ml. Error bars
indicate standard errors.
|
|
HLP 2 binding to LPS.
After taking into account any
nonspecific binding by subtracting binding to a blank chip surface,
450 ± 50 resonance units of HLP 2 bound to 787 ± 100 resonance units of LPS, which is indicative of a specific
interaction between HLP 2 and LPS.
Effects of HLP 2 on permeabilization of E. coli.
Treatment of E. coli with peptide HLP 2 at the MIC for
2 h resulted in a shift of both forward and side light scatter
(Fig. 3), indicating a change in size or
morphology (29).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
Typical side and forward light scatter of control
bacteria (black) and bacteria incubated with HLP 2 for 2 h
(grey).
|
|
Electron microscopy studies of E. coli cells
treated with HLP 2.
Upon exposure of E. coli to
HLP 2 at the MIC and half the MIC for 2 h, TEM revealed clumping
of the cytoplasm and the presence of ghost cells (cells which have no
cytoplasm but still have a cell wall) (Fig.
4b) as compared to control cells (Fig.
4a). At half the MIC, cytoplasmic clumping and enlargement of the
bacteria, caused by blistering of the outer membrane, were observed
(Fig. 4c, d, and e). The outer membrane was observed to separate,
particularly at the ends of the cells or at the junction of dividing
cells. No changes were seen at concentrations lower than half the MIC or after 1 h at the MIC or half the MIC. The change in the
morphology of bacteria at the MIC after 120 min is consistent with the
forward and side light scatter differences shown in Fig. 3.
 |
DISCUSSION |
We have previously shown that the loop region of human
lactoferricin contains an amphipathic
-helical region exposed on the outer surface of lactoferrin on helix 1 and that a synthetic
11-amino-acid peptide from this region, HLP 2, has bactericidal
activity towards E. coli (34). It has
recently been reported that the homologous peptide from
bovine lactoferrin adopted an alpha-helical structure in both
trifluoroethanol and sodium dodecyl sulfate (25), indicating that hydrophobic conditions are required for maintenance of the alpha-helical structure. We have now demonstrated by using surface plasmon resonance that HLP 2 binds specifically to LPS of E. coli O111, showing the importance of this region to binding and
antimicrobial pathogenesis. Previous evidence, obtained by using
recombinant human lactoferrin mutated at residues 28 to 34, has shown
that this region on the whole molecule is involved in binding to
LPS (12). However, other sites may also play a role in
binding, such as the arginine cradle proposed by Mann et al.
(28), in which arginines 2, 3, and 4 at the amino terminus,
in combination with the cationic region on helix 1, form a positively
charged cluster on the outer surface of human lactoferrin. The HLP 2 region is likely to play two roles in vivo, first within the whole
human lactoferrin molecule and second as the peptide fragment
lactoferricin, liberated after enzymatic degradation of lactoferrin.
However, the mechanisms of action of lactoferrin and lactoferricin may well be different, as the free peptide fragment has enhanced
antibacterial activity compared to lactoferrin (4). Although
the bactericidal actions of lactoferrin and lactoferricin may differ,
the HLP 2 LPS recognition site probably plays an important role in
initial bacterial-protein-peptide interactions.
The orientations of the charged amino acids play an important part in
the ability of HLP 2 to exert its antimicrobial activity, as seen by
the large reduction in antimicrobial activity when proline is
substituted for methionine. This substitution was predicted, by
molecular modelling, to disrupt the helix and therefore the orientations of charged amino acids (8). Conformational
changes occur within each lobe of human lactoferrin upon binding of
iron, when the two domains of each lobe come together, with major
structural changes occurring around the hinge region and subtle
differences occurring throughout the rest of the molecule
(18). The differences in charge orientation at the HLP 2 region on helix 1 between the apolactoferrin and hololactoferrin could
account for the inability of the holo form to exert antimicrobial
activity (3). It has already been established that the
affinity of apo human serum transferrin for the human transferrin
receptor is lower than that of the diferric form, and in addition,
subtle changes in the conformation of the diferric protein, as a result
of a mutation close to one of the metal binding sites, reduce its
affinity for the receptor (16).
We have used flow cytometry to investigate how HLP 2 exerts its action
on E. coli O111 with the aid of specific markers.
Exposure of the bacteria to HLP 2 results in the collapse of membrane
potential, leading to pore formation, as shown by PI fluorescence, and
causing a collapse in membrane integrity. This is followed by
distortion of the cell morphology, as shown by the forward and side
light scatter, which finally results in cell lysis. Lysis results in the release of proteases, which could lead to partial proteolysis of
the peptide and a reduction in its effective concentration. As the
D form of the peptide is likely to be more resistant to proteolysis, this could explain the enhanced potency of HLP 7, the
D form of HLP 2, against E. coli O111, a
Klebsiella strain, and P. stuartii. From the
results of experiments carried out either in the presence of the
metabolic inhibitor CCCP or at 4°C, we can conclude that the peptide
acts at the membrane surface and not at the metabolic level. The
results of our studies using flow cytometry indicate that HLP 2 exerts
its antimicrobial effect by a mechanism similar to that of other
cationic peptides which act at the bacterial cell membrane. The
proposed mechanism by which cationic peptides exert their antimicrobial
activity is by interacting with negatively charged divalent cation
binding sites on the surface LPS, disrupting these sites and leading to uptake of peptide across the outer membrane. The affected membrane is
thought to form channels which allow leakage of cytoplasmic molecules
and lead to cell death (20). The differences between HLP 2 and other natural cationic peptides (36) are the
comparatively low potency and relatively slow mode of action of HLP 2. We are therefore able to study how the peptide may act and thus gain insight into how HLP 2 and other alpha-helical cationic peptides may
exert their activities. The timing of collapse of membrane potential
(10 min), collapse of integrity (30 min), and cell lysis (within 2 h) suggests that HLP 2 initially attaches to a site on the LPS, leading
to an interaction between the peptide and outer membrane (OM). This is
further supported by the TEM micrographs, in which the OM was observed
to detach at specific cell sites, either at the point of division or at
the peripheral ends of the cells, without loss of structural rigidity.
Differences in LPS concentration at different points along the OM could
account for the specific detachment. The TEM results obtained in this
study are different from these previously shown for lactoferrin
(13) or lactoferricin (38), which cause
electron-dense blisters, indicating that lactoferrin or lactoferricin
simply binds at the cell surface, without penetration, whereas HLP 2 enters the OM.
The increased potency against S. aureus compared with
that against E. coli can be explained by
differences in the structure of the bacterial cell wall. It is likely
that HLP 2 has a different mechanism of action towards S. aureus than towards E. coli because of the absence
of LPS. The difference between the activities of HLP 1 and HLP 2 against S. aureus could be explained by differences in
peptide size, allowing uptake of HLP 2 rather than HLP 1, but it is
more likely to be due to differences in flexibility and conformation if
the peptide binds to the peptidoglycan. This would also explain
why HLP 6 still has activity against S. aureus. Differences in the composition of the bacterial cell wall
and, in the case of gram-negative bacteria, differences in the
structure of LPS which prevent bacterial interactions could account for
the observations that certain bacteria are resistant to HLP 2 and for
the differences in activity between those bacteria which are
susceptible to HLP 2. In vivo, this may be important in establishing a
bacterial flora.
We have been able to propose for the first time a mechanism of action
for how the loop region of helix 1 in human lactoferrin, both in the
whole protein and as a liberated peptide, can exert its antimicrobial
activity. We have shown that both the helix and the charge are
important for antimicrobial activity against E. coli
and that subtle differences in charge orientation can cause significant
differences in potency. The differences in potency between the free
peptide and lactoferrin can be explained by the degree to which the
helix can interact with the bacterial membrane as a result of the
increased flexibility of the free peptide, to cause bacterial cell wall
disruption.
 |
ACKNOWLEDGMENTS |
D. S. Chapple was supported by a studentship from the
Special Trustees of St. Thomas' Hospital. Financial support from
Bio-Rad Microscience, United Kingdom, is gratefully acknowledged.
We are grateful to A. I. Mallett, St. John's Institute of
Dermatology, UMDS, St. Thomas's Hospital, for assessing the purity of
the peptides by mass spectrometry; to S. Bansal, Kings College, London,
for peptide synthesis; and to Ken Brady and his team for their guidance
in the use of the electron microscopy facility at UMDS.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Metalloprotein
Research Group, Division of Biochemistry and Molecular Biology, UMDS, Guy's Hospital, London Bridge, London SE1 9RT, United Kingdom. Phone:
(44) 171 955 4525. Fax: (44) 171 955 8881. E-mail:
r.evans{at}umds.ac.uk.
Editor: J. R. McGhee
 |
REFERENCES |
| 1.
|
Akin, D. T.,
M. Q. Lu,
S. Kendall,
J. Rundegren, and R. R. Arnold.
1994.
Bactericidal activity of different forms of lactoferrin.
Adv. Exp. Med. Biol.
357:61-70[Medline].
|
| 2.
|
Appelmelk, B. J.,
Y. Am,
M. Geerts,
B. G. Thijs,
H. A. DeBoar,
D. M. MacLaren,
J. DeGraff, and J. H. Nuijens.
1994.
Lactoferrin is a lipid A-binding protein.
Infect. Immun.
62:2628-2632[Abstract/Free Full Text].
|
| 3.
|
Arnold, R. R.,
R. M. Cole, and J. R. McGhee.
1977.
A bactericidal effect for human lactoferrin.
Science
197:263-265[Abstract/Free Full Text].
|
| 4.
|
Bellamy, W.,
M. Takase,
K. Yamauchi,
H. Wakabayashi,
K. Kawase, and M. Tomita.
1992.
Identification of the bactericidal domain of lactoferrin.
Biochim. Biophys. Acta
1121:130-136[Medline].
|
| 5.
|
Bortner, C. A.,
R. D. Miller, and R. R. Arnold.
1986.
Bactericidal effect of lactoferrin on Legionella pneumophila.
Infect. Immun.
51:373-377[Abstract/Free Full Text].
|
| 6.
|
Brock, J. H.
1980.
Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the new-born infant.
Arch. Dis. Child.
55:417-421[Medline].
|
| 7.
|
Bullen, J. J.,
H. J. Rogers, and L. Leigh.
1972.
Iron-binding proteins in milk and resistance to Escherichia coli infection in infants.
Br. Med. J.
1:69-75.
|
| 8.
| Chapple, D. S., D. J. Mason, C. L. Joannou, J. K. Shergill, E. W. Odell, V. Gant, and
R. W. Evans. A helical region on human lactoferrin its role
in antimicrobial pathogenesis. In G. Spik, D. Legrand, J. Mazurier, J.-P. Perraudin, and A. Pierce (ed.), Advances in
lactoferrin research, in press. Plenum Publishing Corporation, New
York, N.Y.
|
| 9.
|
Christensen, B.,
J. Fink,
R. B. Merrifield, and D. Mauzerall.
1988.
Channel-forming properties of cecropins and related model compounds incorporated into planar lipid membranes.
Proc. Natl. Acad. Sci. USA
85:5072-5076[Abstract/Free Full Text].
|
| 10.
|
David, S. A.,
V. I. Manthan, and P. Balaram.
1992.
Interaction of mellitin with endotoxic lipid A.
Biochim. Biophys. Acta
1123:269-274[Medline].
|
| 11.
|
Duclohier, H.,
G. Molle, and G. Spach.
1989.
Antimicrobial peptide magainin I from Xenopus skin forms anion-permeable channels in planar lipid bilayers.
Biophys. J.
56:1017-1021[Abstract/Free Full Text].
|
| 12.
|
Elass-Rochard, E.,
A. Roseanu,
D. Legrand,
M. Trif,
V. Salmon,
C. Motas,
J. Montreuil, and G. Spik.
1995.
Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high affinity binding to Escherichia coli 055B5 lipopolysaccharide.
Biochem. J.
312:839-845.
|
| 13.
|
Ellison, R. T., III, and T. J. Giehl.
1991.
Killing of Gram-negative bacteria by lactoferrin and lysozyme.
J. Clin. Invest.
88:1080-1091.
|
| 14.
|
Ellison, R. T., III,
T. J. Giehl, and F. M. LaForce.
1988.
Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin.
Infect. Immun.
56:2774-2780[Abstract/Free Full Text].
|
| 15.
|
Erdei, J.,
A. Forsgren, and A. S. Naidu.
1994.
Lactoferrin binds to porins OmpF and OmpC in Escherichia coli.
Infect. Immun.
62:1236-1240[Abstract/Free Full Text].
|
| 16.
|
Evans, R. W.,
J. B. Crawley,
R. C. Garratt,
J. G. Grossmann,
M. Neu,
A. Aitken,
K. J. Patel,
A. Meilak,
C. Wong,
J. Singh,
A. Bomford, and S. S. Hasnain.
1994.
Characterisation and structural analysis of a functional human serum transferrin variant and implications for receptor recognition.
Biochemistry
33:12512-12520[Medline].
|
| 17.
|
Gant, V. A.,
G. Warnes,
I. Phillips, and G. F. Savage.
1993.
The application of flow cytometry to the study of bacterial responses to antibiotics.
J. Med. Microbiol.
23:83-88[Abstract].
|
| 18.
|
Grossmann, J. G.,
M. Neu,
E. Pantos,
F. J. Schwab,
R. W. Evans,
E. Townes-Andrews,
H. Appel,
W. G. Thies, and S. S. Hasnain.
1992.
X-ray solution scattering reveals conformational changes upon iron uptake in lactoferrin, serum and ovo-transferrins.
J. Mol. Biol.
225:811-819[Medline].
|
| 19.
|
Habermann, E., and J. Jentsch.
1967.
Sequence analysis of melittin from tryptic and peptic degradation products.
Hoppe-Seyler's Z. Physiol. Chem.
348:37-50[Medline].
|
| 20.
|
Hancock, R. E. W.
1997.
Peptide antibiotics.
Lancet
349:418-422[Medline].
|
| 21.
|
Hultmark, D.,
H. Steiner,
T. Rasmuson, and H. G. Boman.
1980.
Insect immunity. Purification and properties of three inducible bactericidal proteins from the hemolymph of immunised pupae of Hyalphora cecropia.
Eur. J. Biochem.
106:7-16[Medline].
|
| 22.
|
Johansson, B.
1960.
Isolation of an iron-containing red protein from human milk.
Acta Chem. Scand.
14:510-512.
|
| 23.
|
Kagan, B. L.,
M. E. Selsted,
T. Ganz, and R. I. Lehrer.
1990.
Antimicrobial defensin peptides form voltage dependent ion-permeable channels in planar lipid bilayer membranes.
Proc. Natl. Acad. Sci. USA
87:210-214[Abstract/Free Full Text].
|
| 24.
|
Kalmar, J. R., and R. R. Arnold.
1988.
Killing of Actinobacillus actinomycetemcomitans by human lactoferrin.
Infect. Immun.
56:2552-2557[Abstract/Free Full Text].
|
| 25.
|
Kang, J. H.,
M. K. Lee,
K. L. Kim, and K. S. Hahan.
1996.
Structure-biological activity relationship of 11-residue highly basic peptide segment of bovine lactoferrin.
Int. J. Peptide Protein Res.
48:357-363[Medline].
|
| 26.
|
Kaprelyants, A. S., and D. B. Kell.
1992.
Rapid assessment of bacterial viability and vitality by rhodamine 123 and flow-cytometry.
J. Appl. Bacteriol.
72:410-422.
|
| 27.
|
Kuziemko, G. M.,
M. Stroh, and R. C. Stevens.
1996.
Cholera toxin binding affinity and specificity for gangliosides determined by surface plasmon resonance.
Biochemistry
35:6375-6384[Medline].
|
| 28.
|
Mann, D. M.,
E. Romm, and M. Migliorini.
1994.
Delineation of glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin.
J. Biol. Chem.
269:23661-23667[Abstract/Free Full Text].
|
| 29.
|
Mason, D. J.,
E. G. M. Power,
H. Talsania,
I. Phillips, and V. Gant.
1995.
Antibacterial action of ciprofloxacin.
J. Antimicrob. Chemother.
39:2752-2758.
|
| 30.
|
Mason, D. J.,
R. Allman,
J. M. Stark, and D. Lloyd.
1994.
Rapid estimation of bacterial antibiotic susceptibility.
J. Microsc.
176:8-16[Medline].
|
| 31.
|
Masson, P. L.,
J. F. Heremans, and C. Dive.
1966.
An iron-binding protein common to many external secretions.
Clin. Chim. Acta
14:735-739.
|
| 32.
|
Masson, P. L.,
J. F. Heremans, and E. Schonne.
1969.
Lactoferrin, an iron-binding protein in neutrophilic leukocytes.
J. Exp. Med.
130:643-658[Abstract].
|
| 33.
|
Matsuzaki, K.,
M. Harada,
T. Handa,
S. Funakoshi,
N. Fujii,
H. Yajima, and K. Miyajima.
1989.
Magainin 1-induced leakage of entrapped calcein out of negatively-charged lipid vesicles.
Biochem. Biophys. Acta
981:130-134[Medline].
|
| 34.
|
Odell, E. W.,
R. Sarra,
M. Foxworthy,
D. S. Chapple, and R. W. Evans.
1996.
Antibacterial activity of peptides homologous to a loop region in human lactoferrin.
FEBS Lett.
382:175-178[Medline].
|
| 35.
|
Oram, J. D., and B. Reiter.
1968.
Inhibition of bacteria by lactoferrin and other iron-chelating agents.
Biochim. Biophys. Acta
170:351-365[Medline].
|
| 36.
|
Skerlavaj, B.,
D. Romeo, and R. Gennaro.
1990.
Rapid membrane permeabilization and inhibition of vital functions of gram-negative bacteria by bactenecins.
Infect. Immun.
58:3724-3730[Abstract/Free Full Text].
|
| 37.
|
Terwilliger, T. C.,
L. Weissman, and D. Eisenberg.
1982.
The structure of melittin in the form I crystals and its implication for melittin's lytic and surface activities.
Biophys. J.
37:353-361[Abstract/Free Full Text].
|
| 38.
|
Yamauchi, K.,
M. Tomita,
T. J. Giehl, and R. T. Ellison, III.
1993.
Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment.
Infect. Immun.
61:719-728[Abstract/Free Full Text].
|
| 39.
|
Zasloff, M.
1987.
Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor.
Proc. Natl. Acad. Sci. USA
84:5449-5453[Abstract/Free Full Text].
|
Infect Immun, June 1998, p. 2434-2440, Vol. 66, No. 6
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Shalev, D. E., Rotem, S., Fish, A., Mor, A.
(2006). Consequences of N-Acylation on Structure and Membrane Binding Properties of Dermaseptin Derivative K4-S4-(1-13). J. Biol. Chem.
281: 9432-9438
[Abstract]
[Full Text]
-
Hunter, H. N., Demcoe, A. R., Jenssen, H., Gutteberg, T. J., Vogel, H. J.
(2005). Human Lactoferricin Is Partially Folded in Aqueous Solution and Is Better Stabilized in a Membrane Mimetic Solvent. Antimicrob. Agents Chemother.
49: 3387-3395
[Abstract]
[Full Text]
-
Radzishevsky, I. S., Rotem, S., Zaknoon, F., Gaidukov, L., Dagan, A., Mor, A.
(2005). Effects of Acyl versus Aminoacyl Conjugation on the Properties of Antimicrobial Peptides. Antimicrob. Agents Chemother.
49: 2412-2420
[Abstract]
[Full Text]
-
Stokes, R. H., Oakhill, J. S., Joannou, C. L., Gorringe, A. R., Evans, R. W.
(2005). Meningococcal Transferrin-Binding Proteins A and B Show Cooperation in Their Binding Kinetics for Human Transferrin. Infect. Immun.
73: 944-952
[Abstract]
[Full Text]
-
Shaper, M., Hollingshead, S. K., Benjamin, W. H. Jr., Briles, D. E.
(2004). PspA Protects Streptococcus pneumoniae from Killing by Apolactoferrin, and Antibody to PspA Enhances Killing of Pneumococci by Apolactoferrin. Infect. Immun.
72: 5031-5040
[Abstract]
[Full Text]
-
Chapple, D. S., Hussain, R., Joannou, C. L., Hancock, R. E. W., Odell, E., Evans, R. W., Siligardi, G.
(2004). Structure and Association of Human Lactoferrin Peptides with Escherichia coli Lipopolysaccharide. Antimicrob. Agents Chemother.
48: 2190-2198
[Abstract]
[Full Text]
-
Velliyagounder, K., Kaplan, J. B., Furgang, D., Legarda, D., Diamond, G., Parkin, R. E., Fine, D. H.
(2003). One of Two Human Lactoferrin Variants Exhibits Increased Antibacterial and Transcriptional Activation Activities and Is Associated with Localized Juvenile Periodontitis. Infect. Immun.
71: 6141-6147
[Abstract]
[Full Text]
-
Majerle, A., Kidric, J., Jerala, R.
(2003). Enhancement of antibacterial and lipopolysaccharide binding activities of a human lactoferrin peptide fragment by the addition of acyl chain. J Antimicrob Chemother
51: 1159-1165
[Abstract]
[Full Text]
-
Bengoechea, J. A., Brandenburg, K., Arraiza, M. D., Seydel, U., Skurnik, M., Moriyon, I.
(2003). Pathogenic Yersinia enterocolitica Strains Increase the Outer Membrane Permeability in Response to Environmental Stimuli by Modulating Lipopolysaccharide Fluidity and Lipid A Structure. Infect. Immun.
71: 2014-2021
[Abstract]
[Full Text]
-
Navon-Venezia, S., Feder, R., Gaidukov, L., Carmeli, Y., Mor, A.
(2002). Antibacterial Properties of Dermaseptin S4 Derivatives with In Vivo Activity. Antimicrob. Agents Chemother.
46: 689-694
[Abstract]
[Full Text]
-
Nibbering, P. H., Ravensbergen, E., Welling, M. M., van Berkel, L. A., van Berkel, P. H. C., Pauwels, E. K. J., Nuijens, J. H.
(2001). Human Lactoferrin and Peptides Derived from Its N Terminus Are Highly Effective against Infections with Antibiotic-Resistant Bacteria. Infect. Immun.
69: 1469-1476
[Abstract]
[Full Text]
-
Lupetti, A., Paulusma-Annema, A., Welling, M. M., Senesi, S., van Dissel, J. T., Nibbering, P. H.
(2000). Candidacidal Activities of Human Lactoferrin Peptides Derived from the N Terminus. Antimicrob. Agents Chemother.
44: 3257-3263
[Abstract]
[Full Text]
-
Levy, O.
(2000). Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. Blood
96: 2664-2672
[Abstract]
[Full Text]
-
Sallmann, F. R., Baveye-Descamps, S., Pattus, F., Salmon, V., Branza, N., Spik, G., Legrand, D.
(1999). Porins OmpC and PhoE of Escherichia coli as Specific Cell-surface Targets of Human Lactoferrin. BINDING CHARACTERISTICS AND BIOLOGICAL EFFECTS. J. Biol. Chem.
274: 16107-16114
[Abstract]
[Full Text]
-
Hancock, R. E. W., Chapple, D. S.
(1999). Peptide Antibiotics. Antimicrob. Agents Chemother.
43: 1317-1323
[Full Text]
-
Wakabayashi, H., Matsumoto, H., Hashimoto, K., Teraguchi, S., Takase, M., Hayasawa, H.
(1999). N-Acylated and D Enantiomer Derivatives of a Nonamer Core Peptide of Lactoferricin B Showing Improved Antimicrobial Activity. Antimicrob. Agents Chemother.
43: 1267-1269
[Abstract]
[Full Text]